EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Evommune, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.27+0.10 (+1.93%)
Close on Oct 19, 2026
- Market cap
- $190.43M
- P/E (TTM)
- –
- Dividend yield
- –
Evommune statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Evommune | Industry median |
|---|---|---|
| Market Cap | $191.26M | $164.85M |
| Enterprise Value | -$9.53M | $87.06M |
| PS Ratio | 19.13 | 3.60 |
| PB Ratio | 0.69 | 2.03 |
| P/TBV Ratio | 0.69 | 2.31 |
Enterprise value
| Measure | Evommune | Industry median |
|---|---|---|
| EV / Sales | -0.95 | 2.43 |
Income (trailing twelve months)
| Measure | Evommune | Industry median |
|---|---|---|
| Revenue | $10.00M | $57.94M |
| Operating Income | -$101.89M | -$21.44M |
| Net Income | -$94.67M | -$22.46M |
| EBITDA | -$101.29M | -$16.91M |
Margins
| Measure | Evommune | Industry median |
|---|---|---|
| Operating Margin | -1018.9% | -44.5% |
| Profit Margin | -946.7% | -39.2% |
| EBITDA Margin | -1012.9% | -31.3% |
| FCF Margin | -746.5% | -8.85% |
Returns
| Measure | Evommune | Industry median |
|---|---|---|
| Return on Equity (ROE) | -178.0% | -53.1% |
| Return on Assets (ROA) | -31.4% | -41.0% |
| Return on Capital Employed (ROCE) | -35.8% | -37.8% |
Balance sheet
| Measure | Evommune | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $200.79M | $62.42M |
| Net Cash (Debt) | $200.79M | $15.68M |
| Net Cash Per Share | $5.53 | $0.66 |
| Equity (Book Value) | $277.59M | $48.79M |
| Book Value Per Share | $7.65 | $1.36 |
| Tangible Book Value | $277.59M | $23.06M |
| Working Capital | $186.76M | $75.77M |
Financial position
| Measure | Evommune | Industry median |
|---|---|---|
| Current Ratio | 11.68 | 3.30 |
| Quick Ratio | 11.48 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Evommune | Industry median |
|---|---|---|
| Operating Cash Flow | -$74.15M | -$12.35M |
| Capital Expenditures | -$501.00K | -$1.06M |
| Free Cash Flow | -$74.65M | -$20.28M |
| FCF Per Share | -$2.06 | -$0.42 |
Efficiency
| Measure | Evommune | Industry median |
|---|---|---|
| Asset Turnover | 0.03 | 0.38 |
| Revenue Per Employee | $208.33K | $398.96K |
| Profits Per Employee | -$1.97M | -$703.34K |
| Employee Count | 48 | 74 |
Dividends and yields
| Measure | Evommune | Industry median |
|---|---|---|
| Earnings Yield | -49.5% | -22.7% |
| FCF Yield | -39.0% | -9.07% |
Shares
| Measure | Evommune | Industry median |
|---|---|---|
| Shares Outstanding | 36,292,100 | 58,179,650 |
| Shares Change (QoQ) | 0.73% | 0.54% |
| Float | 17,555,500 | 49,173,100 |
| Shares Held by Insiders | 51.6% | 11.6% |
| Shares Held by Institutions | 95.4% | 59.4% |
Taxes
| Measure | Evommune | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Evommune | Industry median |
|---|---|---|
| Altman Z-Score | 3.10 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Evommune's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.